Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

Emanuele Pontali; Stefano Volpi; Giancarlo Antonucci; Marco Castellaneta; Davide Buzzi; Francesca Tricerri; Alessia Angelelli; Roberta Caorsi; Marcello Feasi; Francesca Calautti; Elio Castagnola; Gian Andrea Rollandi; Angelo Ravelli; Giovanni Cassola; Marco Gattorno

doi:10.1016/j.jaci.2020.05.002

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

Emanuele Pontali, Stefano Volpi, Giancarlo Antonucci, Marco Castellaneta, Davide Buzzi, Francesca Tricerri, Alessia Angelelli, Roberta Caorsi, Marcello Feasi, Francesca Calautti, Elio Castagnola, Gian Andrea Rollandi, Angelo Ravelli, Giovanni Cassola, Marco Gattorno

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	213-215
Number of pages	3
Journal	J. Allergy Clin. Immunol.
Volume	146
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2020.05.002
Publication status	Published - Jul 2020

Keywords

Administration, Intravenous
Adult
Antirheumatic Agents/administration & dosage
Betacoronavirus
COVID-19
Coronavirus Infections/complications
Female
Humans
Interleukin 1 Receptor Antagonist Protein/administration & dosage
Male
Middle Aged
Pandemics
Pneumonia, Viral/complications
SARS-CoV-2
Treatment Outcome

Access to Document

10.1016/j.jaci.2020.05.002

Cite this

Pontali, E., Volpi, S., Antonucci, G., Castellaneta, M., Buzzi, D., Tricerri, F., Angelelli, A., Caorsi, R., Feasi, M., Calautti, F., Castagnola, E., Rollandi, G. A., Ravelli, A., Cassola, G., & Gattorno, M. (2020). Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J. Allergy Clin. Immunol., 146(1), 213-215. https://doi.org/10.1016/j.jaci.2020.05.002

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. / Pontali, Emanuele; Volpi, Stefano; Antonucci, Giancarlo; Castellaneta, Marco; Buzzi, Davide; Tricerri, Francesca; Angelelli, Alessia; Caorsi, Roberta; Feasi, Marcello; Calautti, Francesca; Castagnola, Elio; Rollandi, Gian Andrea; Ravelli, Angelo; Cassola, Giovanni; Gattorno, Marco.

In: J. Allergy Clin. Immunol., Vol. 146, No. 1, 07.2020, p. 213-215.

Research output: Contribution to journal › Article › peer-review

Pontali, E, Volpi, S, Antonucci, G, Castellaneta, M, Buzzi, D, Tricerri, F, Angelelli, A, Caorsi, R, Feasi, M, Calautti, F, Castagnola, E, Rollandi, GA, Ravelli, A, Cassola, G & Gattorno, M 2020, 'Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease', J. Allergy Clin. Immunol., vol. 146, no. 1, pp. 213-215. https://doi.org/10.1016/j.jaci.2020.05.002

Pontali, Emanuele ; Volpi, Stefano ; Antonucci, Giancarlo ; Castellaneta, Marco ; Buzzi, Davide ; Tricerri, Francesca ; Angelelli, Alessia ; Caorsi, Roberta ; Feasi, Marcello ; Calautti, Francesca ; Castagnola, Elio ; Rollandi, Gian Andrea ; Ravelli, Angelo ; Cassola, Giovanni ; Gattorno, Marco. / Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. In: J. Allergy Clin. Immunol. 2020 ; Vol. 146, No. 1. pp. 213-215.

@article{afffb99ef5bc45f0a5d30c68701d6380,

title = "Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease",

keywords = "Administration, Intravenous, Adult, Antirheumatic Agents/administration & dosage, Betacoronavirus, COVID-19, Coronavirus Infections/complications, Female, Humans, Interleukin 1 Receptor Antagonist Protein/administration & dosage, Male, Middle Aged, Pandemics, Pneumonia, Viral/complications, SARS-CoV-2, Treatment Outcome",

author = "Emanuele Pontali and Stefano Volpi and Giancarlo Antonucci and Marco Castellaneta and Davide Buzzi and Francesca Tricerri and Alessia Angelelli and Roberta Caorsi and Marcello Feasi and Francesca Calautti and Elio Castagnola and Rollandi, {Gian Andrea} and Angelo Ravelli and Giovanni Cassola and Marco Gattorno",

year = "2020",

month = jul,

doi = "10.1016/j.jaci.2020.05.002",

language = "English",

volume = "146",

pages = "213--215",

journal = "J. Allergy Clin. Immunol.",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "1",

}

TY - JOUR

T1 - Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

AU - Pontali, Emanuele

AU - Volpi, Stefano

AU - Antonucci, Giancarlo

AU - Castellaneta, Marco

AU - Buzzi, Davide

AU - Tricerri, Francesca

AU - Angelelli, Alessia

AU - Caorsi, Roberta

AU - Feasi, Marcello

AU - Calautti, Francesca

AU - Castagnola, Elio

AU - Rollandi, Gian Andrea

AU - Ravelli, Angelo

AU - Cassola, Giovanni

AU - Gattorno, Marco

PY - 2020/7

Y1 - 2020/7

KW - Administration, Intravenous

KW - Adult

KW - Antirheumatic Agents/administration & dosage

KW - Betacoronavirus

KW - COVID-19

KW - Coronavirus Infections/complications

KW - Female

KW - Humans

KW - Interleukin 1 Receptor Antagonist Protein/administration & dosage

KW - Male

KW - Middle Aged

KW - Pandemics

KW - Pneumonia, Viral/complications

KW - SARS-CoV-2

KW - Treatment Outcome

U2 - 10.1016/j.jaci.2020.05.002

DO - 10.1016/j.jaci.2020.05.002

M3 - Article

C2 - 32437739

VL - 146

SP - 213

EP - 215

JO - J. Allergy Clin. Immunol.

JF - J. Allergy Clin. Immunol.

SN - 0091-6749

IS - 1

ER -